Saturday 17 October 2026
Export GSK’s income statement to Excel — free account
GSK PLC Sponsored ADR
GSK Healthcare Drug Manufacturers General
GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024. In the quarter to June 2026, revenue grew 5.81%, EPS fell 69.5%, free cash flow grew 54.8% and total debt rose 5.61%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
49.55
0.53
+1.08%
Follow GSK
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
13.22 | 21.14 | 12.42 | 4.07 | 14.64 | 9.98 | 15.80 | 15.68 | 37.40 | 64.73 |
Piotroski F-Score |
9 | 5 | 5 | 6 | 6 | 7 | 6 | 7 | 6 | 5 |
P/S ratio |
2.31 | 1.72 | 2.01 | 1.96 | 1.88 | 1.67 | 2.16 | 1.83 | 1.86 | 2.01 |
Altman Z-Score |
2.12 | 1.54 | 1.80 | 1.59 | 1.42 | 1.41 | 1.44 | 1.30 | 1.00 | 1.06 |
Altman Z″-Score (non-manufacturers) |
1.37 | 0.66 | 1.19 | 0.94 | 0.83 | 1.14 | 0.71 | (0.04) | (1.06) | (0.16) |
P/FCF ratio |
15.39 | 14.32 | 13.69 | 10.47 | 10.81 | 7.58 | 11.46 | 7.98 | 11.10 | 12.33 |
Beneish M-Score |
(2.46) | (2.79) | (2.56) | (2.99) | (2.47) | (2.57) | (2.45) | (2.76) | (3.00) | (2.95) |
P/Operating CF |
34.92 | 23.94 | 19.50 | 26.49 | 17.09 | 14.91 | 20.17 | 13.33 | 19.97 | 18.00 |
Dividend Safety Score |
54 | — | — | — | — | — | — | — | — | — |
P/B ratio |
4.72 | 4.12 | 4.77 | 5.69 | 3.01 | 2.74 | 3.97 | 15.32 | 16.05 | 11.24 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
2.74 | 2.13 | 2.43 | 2.40 | 2.46 | 2.28 | 2.91 | 2.54 | 2.29 | 2.50 |
EV/EBITDA |
8.74 | 10.18 | 8.16 | 8.20 | 10.20 | 7.66 | 10.56 | 10.65 | 11.50 | 15.88 |
EV/Operating CF |
11.56 | 10.21 | 10.90 | 9.50 | 10.54 | 9.20 | 12.23 | 9.28 | 9.99 | 10.69 |
EV/FCF |
18.29 | 17.76 | 16.53 | 12.82 | 14.12 | 10.32 | 15.44 | 11.09 | 13.70 | 15.34 |
Quick Ratio |
0.53 | 0.52 | 0.62 | 0.68 | 0.54 | 0.64 | 0.53 | 0.48 | 0.39 | 0.60 |
Current Ratio |
0.82 | 0.78 | 0.88 | 0.91 | 0.79 | 0.91 | 0.81 | 0.75 | 0.60 | 0.88 |
Net Debt/EBITDA |
1.39 | 1.98 | 1.41 | 1.51 | 3.17 | 2.04 | 2.72 | 2.99 | 2.18 | 3.12 |
Debt/Assets |
28.99% | 28.57% | 30.54% | 34.89% | 30.56% | 33.76% | 38.28% | 44.89% | 30.31% | 31.80% |
Debt/Equity |
1.11 | 1.30 | 1.41 | 2.08 | 1.13 | 1.30 | 1.66 | 7.10 | 4.90 | 3.79 |
Asset Turnover |
0.55 | 0.54 | 0.51 | 0.40 | 0.44 | 0.43 | 0.48 | 0.55 | 0.51 | 0.47 |
Operating CF/Net income |
1.35 | 2.55 | 1.37 | 0.50 | 1.81 | 1.47 | 1.73 | 2.32 | 4.52 | 7.12 |
Capex/Depreciation |
(1.23) | (1.09) | (1.00) | (0.89) | (0.97) | (0.39) | (0.71) | (0.74) | (0.97) | (1.11) |
Interest Coverage |
11.32 | 6.01 | 8.52 | 7.32 | 7.91 | 8.73 | 7.63 | 6.87 | 5.57 | 3.53 |
| 39.92% | 20.16% | 43.16% | 88.44% | 21.51% | 29.43% | 41.86% | 102.91% | 35.19% | 12.18% | |
| 9.63% | 4.41% | 8.30% | 20.20% | 5.69% | 7.20% | 6.62% | 6.44% | 2.59% | 1.53% | |
ROIC |
16.44% | 9.64% | 16.53% | 17.47% | 9.45% | 11.74% | 9.97% | 13.39% | 15.39% | 8.72% |
Return on Tangible Assets |
105.05% | 56.88% | 74.71% | 217.01% | 88.84% | 69.47% | 80.24% | 65.94% | 773.74% | 10.71% |
Average Days of Receivables |
86.69 | 85.21 | 93.37 | 92.83 | 89.30 | 81.60 | 80.71 | 78.78 | 75.67 | 81.82 |
Research and Development Expense of Revenue |
23.04% | 20.40% | 20.52% | 18.72% | 15.47% | 14.95% | 13.53% | 12.63% | 14.83% | 13.01% |
Selling, General and Administrative Expense of Revenue |
27.82% | 35.11% | 30.94% | 28.55% | 32.17% | 33.60% | 33.78% | 32.17% | 32.04% | 33.58% |
Intangible Assets out of Total Assets |
0.39 | 0.38 | 0.37 | 0.36 | 0.51 | 0.50 | 0.52 | 0.40 | 0.41 | 0.42 |
Share Based Compensation of Revenue |
1.14% | 1.10% | 1.01% | 1.18% | 0.00% | 1.12% | 1.08% | 1.17% | 1.10% | 1.14% |
Graham Net Nets |
(0.37) | (0.54) | (0.45) | (0.51) | (0.61) | (0.69) | (0.57) | (0.67) | (0.66) | (0.67) |
Graham Number |
29.45 | 17.18 | 23.10 | 34.79 | 31.53 | 33.37 | 28.16 | 11.69 | 7.15 | 6.83 |
Earnings Yield |
7.57% | 4.73% | 8.05% | 24.57% | 6.83% | 10.02% | 6.33% | 6.38% | 2.67% | 1.54% |
Free Cash Flow Yield |
6.50% | 6.98% | 7.31% | 9.55% | 9.25% | 13.19% | 8.73% | 12.53% | 9.01% | 8.11% |
Revenue per Share |
21.27 | 19.67 | 18.62 | 18.02 | 23.44 | 22.00 | 21.78 | 20.93 | 19.91 | 19.44 |
Operating CF per Share |
5.04 | 4.11 | 4.16 | 4.55 | 5.46 | 5.45 | 5.18 | 5.72 | 4.56 | 4.53 |
Capex per Share |
(1.85) | (1.75) | (1.41) | (1.18) | (1.39) | (0.59) | (1.07) | (0.93) | (1.24) | (1.37) |
Free Cash Flow per Share |
3.19 | 2.36 | 2.74 | 3.37 | 4.08 | 4.85 | 4.10 | 4.79 | 3.33 | 3.16 |
Cash per Share |
2.30 | 2.51 | 3.26 | 4.96 | 3.11 | 4.21 | 3.36 | 2.82 | 2.62 | 3.58 |
Shareholders Equity per Share |
10.39 | 8.20 | 7.86 | 6.20 | 14.66 | 13.42 | 11.85 | 2.49 | 2.30 | 3.46 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
10.39 | 8.20 | 7.86 | 6.20 | 14.66 | 13.42 | 11.85 | 2.49 | 2.30 | 3.46 |
Free Cash Flow |
6,455.04 | 4,815.13 | 5,552.77 | 6,786.87 | 8,162.59 | 9,662.10 | 8,115.98 | 9,409.00 | 6,502.00 | 6,134.09 |
Working Capital |
(5,117.87) | (6,006.13) | (3,015.21) | (2,524.51) | (6,870.00) | (2,440.88) | (5,821.39) | (7,426.83) | (13,741.19) | (3,103.63) |
Capital Expenditures |
(3,753.02) | (3,560.23) | (2,865.94) | (2,369.90) | (2,772.20) | (1,176.14) | (2,124.76) | (1,831.35) | (2,413.92) | (2,671.30) |
Net Current Asset Value |
(36,464.69) | (37,544.70) | (34,289.35) | (36,217.66) | (53,748.53) | (50,558.78) | (53,430.60) | (50,010.95) | (47,666.27) | (50,697.71) |
EV/EBIT |
11.29 | 16.65 | 10.94 | 10.94 | 13.52 | 9.98 | 14.10 | 14.26 | 16.91 | 27.37 |
Capex to Sales |
0.09 | 0.09 | 0.08 | 0.07 | 0.06 | 0.03 | 0.05 | 0.04 | 0.06 | 0.07 |
Price to Operating Income |
9.50 | 13.42 | 9.06 | 8.93 | 10.35 | 7.33 | 10.46 | 10.26 | 13.70 | 21.99 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.25 | 0.28 | 0.25 | 0.24 | 0.21 | 0.23 | 0.23 | 0.17 | 0.18 | 0.16 |
Cash ROIC |
13.16% | 11.06% | 12.36% | 14.02% | 11.86% | 13.81% | 11.75% | 20.80% | 20.54% | 15.66% |
Accounts Receivable Turnover |
4.40 | 4.22 | 4.00 | 3.50 | 4.41 | 4.53 | 4.68 | 4.86 | 4.70 | 4.36 |
Accounts Payable Turnover |
0.60 | 0.59 | 0.54 | 0.53 | 0.72 | 0.76 | 0.80 | 0.60 | 0.62 | 0.83 |
Inventory Turnover |
1.58 | 1.64 | 1.61 | 1.65 | 2.04 | 1.97 | 2.03 | 1.89 | 1.89 | 1.78 |
Average Days of Payables |
622.61 | 618.62 | 675.20 | 621.31 | 552.20 | 493.98 | 459.64 | 500.29 | 740.09 | 470.06 |
Days of Inventory on Hand |
239.80 | 228.69 | 234.30 | 196.60 | 181.92 | 186.99 | 182.98 | 195.17 | 196.12 | 200.46 |
Average Receivables |
9,796.20 | 9,505.40 | 9,437.49 | 10,350.69 | 10,632.26 | 9,659.36 | 9,204.94 | 8,472.20 | 8,269.32 | 8,666.95 |
Average Payables |
19,939.76 | 19,652.48 | 19,912.03 | 22,127.11 | 22,238.54 | 19,707.09 | 18,906.10 | 22,881.37 | 21,620.48 | 15,133.93 |
Average Inventory |
7,528.20 | 7,041.69 | 6,602.02 | 7,158.65 | 7,825.53 | 7,646.29 | 7,451.54 | 7,235.61 | 7,038.30 | 7,062.75 |
Average Assets |
78,292.04 | 74,692.05 | 73,895.46 | 91,584.55 | 106,023.95 | 102,516.05 | 89,632.60 | 75,085.17 | 76,368.16 | 80,895.71 |
Average Common Equity |
18,881.89 | 16,319.15 | 14,201.72 | 20,917.56 | 28,032.43 | 25,078.76 | 14,170.72 | 4,699.00 | 5,611.49 | 10,150.41 |
Columns are period end dates